The role of Tau protein in resistance to paclitaxel

Resistance to taxanes, related to limited efficacy of systemic therapy in cancer patients, is multifactorial. Among mechanisms of resistance to taxanes, those related to microtubule-associated proteins (MAP), including protein Tau, are of great importance. Protein Tau (50–64 kD) binds to beta-tubulin in the same place as paclitaxel. In preclinical studies, low expression of Tau in cancer cells was associated with increased sensitivity to paclitaxel. High expression of Tau protein in ER-positive breast cancers indicates resistance to taxane-containing chemotherapy and sensitivity to hormonal treatment. This article reviews current knowledge on predictive value of protein Tau in response to taxanes. Better understanding of its role may facilitate patients selection to this sort of treatment and lead to treatment optimization.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-011-1696-7PMID 21713447PMCID 3162141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.

  2010influential reference
• Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

  2009cited by this paper
• Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

  2009cited by this paper
• Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

  2009cited by this paper
• Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

  2009cited by this paper
• Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma

  2009cited by this paper
• Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.

  2009cited by this paper
• Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.

  2008cited by this paper
• Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.

  2007cited by this paper
• A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

  2007cited by this paper
• Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

  2007cited by this paper
• Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10

  2007cited by this paper
• Tau and tauopathies.

  2007cited by this paper
• Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site

  2007cited by this paper
• Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients

  2006cited by this paper
• Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

  2006cited by this paper
• Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment

  2006cited by this paper
• Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

  2005influential reference
• Repeat motifs of tau bind to the insides of microtubules in the absence of taxol

  2003cited by this paper
• Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.

  2002cited by this paper
• The role of beta-tubulin isotypes in resistance to antimitotic drugs.

  2001cited by this paper
• Structural insight into microtubule function.

  2001cited by this paper
• The role of β-tubulin isotypes in resistance to antimitotic drugs

  2001cited by this paper
• p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.

  2000cited by this paper
• The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review

  1999cited by this paper
• How Taxol stabilises microtubule structure.

  1999cited by this paper
• Phosphorylation of Bcl-2 Is a Marker of M Phase Events and Not a Determinant of Apoptosis*

  1998cited by this paper
• p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.

  1997cited by this paper
• Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

  1997cited by this paper
• Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

  1996cited by this paper
• Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau.

  1993cited by this paper
• A protein factor essential for microtubule assembly.

  1975cited by this paper

• Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies.

  2025cites this paper
• Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions

  2025cites this paper
• Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities

  2025cites this paper
• Interplay Between the Cytoskeleton and DNA Damage Response in Cancer Progression

  2025cites this paper
• Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies.

  2025cites this paper
• Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature

  2025cites this paper
• Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.

  2024cites this paper
• Effect of substituents at the C3´, C3´N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells.

  2024cites this paper
• Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review.

  2024cites this paper
• Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease

  2024cites this paper
• Breast‐to‐brain metastasis is exacerbated with chemotherapy through blood–cerebrospinal fluid barrier and induces Alzheimer's‐like pathology

  2023cites this paper
• Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells

  2023cites this paper
• P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: evidence for a role of tau in cancer.

  2022cites this paper
• Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties

  2022cites this paper
• RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage

  2022cites this paper
• Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma

  2022cites this paper
• High-Intensity Focused Ultrasound Enhanced Anti-Tumor Activities of Paclitaxel in Breast Cancer in vitro and in vivo

  2022influential citation
• The Effect of Tau and Taxol on Polymerization of MCF7 Microtubules In Vitro

  2022cites this paper
• Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment.

  2021cites this paper
• Microtubule Lattice Spacing Governs Cohesive Envelope Formation of Tau Family Proteins

  2021cites this paper
• Tau Stabilizes Chromatin Compaction

  2021cites this paper
• A review on the role of Tau and Stathmin in gastric cancer metastasis.

  2021cites this paper
• Therapeutic strategies to overcome taxane resistance in cancer.

  2021cites this paper
• AITL: Adversarial Inductive Transfer Learning with input and output space adaptation for pharmacogenomics

  2020cites this paper
• Mechanisms of Taxane Resistance

  2020cites this paper
• ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients

  2020cites this paper
• Tau: At the Interface Between Neurodegeneration and Cancer?

  2020cites this paper
• Microtubule-targeting agents and their impact on cancer treatment.

  2020cites this paper
• The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

  2020cites this paper
• Virtual screening of MAP-Tau protein inhibitors from Semecarpus anacardium Linn. leaf extract for cancer prevention

  2020influential citation
• Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

  2020cites this paper
• CMAR_A_215427 7391..7404

  2019cites this paper
• Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel

  2019cites this paper
• Tau repeat regions contain conserved histidine residues that modulate microtubule-binding in response to changes in pH

  2019cites this paper
• Tau repeat regions contain conserved histidine residues that modulate microtubule-binding in response to changes in pH.

  2019cites this paper
• Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT

  2019cites this paper
• Title: IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation Running title: Glioma genotype defines the vascular phenotype

  2019cites this paper
• Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

  2019cites this paper
• Conserved tau microtubule-binding repeat histidines confer pH-dependent tau-microtubule association

  2018cites this paper
• Cytotoxicity of Tanshinone IIA combined with Taxol on drug‐resist breast cancer cells MCF‐7 through inhibition of Tau

  2018cites this paper
• Substituents at the C3′ and C3′N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel

  2018cites this paper
• Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

  2018cites this paper
• Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption

  2018cites this paper
• PRP4K IS A NOVEL HER2-REGULATED MODIFIER OF ANOIKIS AND TAXANE RESISTANCE

  2018cites this paper
• The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells

  2017cites this paper
• Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms

  2017cites this paper
• The Effect of Duloxetine on Tau Protein and Migration in Breast Cancer Cell Line

  2017cites this paper
• Targeting mitotic pathways for endocrine-related cancer therapeutics.

  2017cites this paper
• BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

  2016cites this paper
• Docetaxel Modulates the Delayed Rectifier Potassium Current (IK) and ATP-Sensitive Potassium Current (IKATP) in Human Breast Cancer Cells

  2015cites this paper
• Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

  2015cites this paper
• Neoadjuvant docetaxel/cyclophosphamide in triple-negative breast cancer: predictive value of class III-β tubulin and non-basal subtype.

  2015cites this paper
• Three-Dimensional Collagen Type I Matrix Up-Regulates Nuclear Isoforms of the Microtubule Associated Protein Tau Implicated in Resistance to Paclitaxel Therapy in Ovarian Carcinoma

  2015cites this paper
• MicroRNA-induced drug resistance in gastric cancer.

  2015cites this paper
• FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer

  2015cites this paper
• Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer.

  2015cites this paper
• Predictive and Prognostic Value of the TauProtein in Breast Cancer.

  2015cites this paper
• Differentially expressed proteins in human breast cancer cells sensitive and resistant to paclitaxel.

  2014cites this paper
• Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes.

  2014cites this paper
• Precision treatment for cancer: Role of prognostic and predictive markers

  2014cites this paper
• Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells.

  2014cites this paper
• Collapsin response mediator protein 2 is involved in regulating breast cancer progression

  2014cites this paper
• Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

  2014cites this paper
• The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin

  2014cites this paper
• Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.

  2014cites this paper
• Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.

  2013cites this paper
• Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer

  2013cites this paper
• The effect of some antineoplastic agents on glutathione S-transferase from human erythrocytes

  2013cites this paper
• Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy

  2013cites this paper
• miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.

  2013cites this paper
• Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

  2013cites this paper
• The ClC-3 chloride channel associated with microtubules is a target of paclitaxel in its induced-apoptosis

  2013cites this paper
• Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

  2013cites this paper
• The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective Activities

  2012cites this paper
• Preclinical Development TPI-287 , a New Taxane Family Member , Reduces the Brain Metastatic Colonization of Breast Cancer Cells

  2012cites this paper
• Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

  2012cites this paper
• TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

  2012cites this paper
• Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.

  2012cites this paper